NCCN Guidelines Insights: Bone Cancer, Version 2.2017

Restricted access

The NCCN Guidelines for Bone Cancer provide interdisciplinary recommendations for treating chordoma, chondrosarcoma, giant cell tumor of bone, Ewing sarcoma, and osteosarcoma. These NCCN Guidelines Insights summarize the NCCN Bone Cancer Panel's guideline recommendations for treating Ewing sarcoma. The data underlying these treatment recommendations are also discussed.

Provided content development and/or authorship assistance.

  • 1.

    SEER Cancer Statistics Fact Sheets: Bone and Joint Cancer. Bethesda, MD: National Cancer Institute; 2014. Available at: http://seer.cancer.gov/statfacts/html/bones.html. Accessed July 30, 2014.

    • Search Google Scholar
    • Export Citation
  • 2.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:730.

  • 3.

    Bernstein M, Kovar H, Paulussen M. Ewing's sarcoma family of tumors: current management. Oncologist 2006;11:503519.

  • 4.

    Subbiah V, Anderson P, Lazar AJ. Ewing's sarcoma: standard and experimental treatment options. Curr Treat Options Oncol 2009;10:126140.

  • 5.

    Federman N, Bernthal N, Eilber FC, Tap WD. The multidisciplinary management of osteosarcoma. Curr Treat Options Oncol 2009;10:8293.

  • 6.

    Cotterill SJ, Ahrens S, Paulussen M. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000;18:31083114.

    • Search Google Scholar
    • Export Citation
  • 7.

    Kager L, Zoubek A, Potschger U. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003;21:20112018.

    • Search Google Scholar
    • Export Citation
  • 8.

    de Alava E, Gerald WL. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J Clin Oncol 2000;18:204213.

  • 9.

    Delattre O, Zucman J, Melot T. The Ewing family of tumors—a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994;331:294299.

    • Search Google Scholar
    • Export Citation
  • 10.

    Denny CT. Gene rearrangements in Ewing's sarcoma. Cancer Invest 1996;14:8388.

  • 11.

    Burchill SA. Molecular abnormalities in Ewing's sarcoma. Expert Rev Anticancer Ther 2008;8:16751687.

  • 12.

    Glaubiger DL, Makuch R, Schwarz J. Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcoma. Cancer 1980;45:22132219.

    • Search Google Scholar
    • Export Citation
  • 13.

    Gobel V, Jurgens H, Etspuler G. Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol 1987;113:187191.

    • Search Google Scholar
    • Export Citation
  • 14.

    Ahrens S, Hoffmann C, Jabar S. Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study. Med Pediatr Oncol 1999;32:186195.

    • Search Google Scholar
    • Export Citation
  • 15.

    Bacci G, Longhi A, Ferrari S. Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol 2006;45:469475.

    • Search Google Scholar
    • Export Citation
  • 16.

    Rodriguez-Galindo C, Liu T, Krasin MJ. Analysis of prognostic factors in Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies. Cancer 2007;110:375384.

    • Search Google Scholar
    • Export Citation
  • 17.

    Serlo J, Helenius I, Vettenranta K. Surgically treated patients with axial and peripheral Ewing's sarcoma family of tumours: a population based study in Finland during 1990-2009. Eur J Surg Oncol 2015;41:893898.

    • Search Google Scholar
    • Export Citation
  • 18.

    Grevener K, Haveman LM, Ranft A. Management and outcome of Ewing sarcoma of the head and neck. Pediatr Blood Cancer 2016;63:604610.

  • 19.

    Cangir A, Vietti TJ, Gehan EA. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer 1990;66:887893.

    • Search Google Scholar
    • Export Citation
  • 20.

    Lee J, Hoang BH, Ziogas A, Zell JA. Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry. Cancer 2010;116:19641973.

    • Search Google Scholar
    • Export Citation
  • 21.

    Bacci G, Boriani S, Balladelli A. Treatment of nonmetastatic Ewing's sarcoma family tumors of the spine and sacrum: the experience from a single institution. Eur Spine J 2009;18:10911095.

    • Search Google Scholar
    • Export Citation
  • 22.

    Kissane JM, Askin FB, Foulkes M. Ewing's sarcoma of bone: clinicopathologic aspects of 303 cases from the Intergroup Ewing's Sarcoma Study. Hum Pathol 1983;14:773779.

    • Search Google Scholar
    • Export Citation
  • 23.

    Gupta AA, Pappo A, Saunders N. Clinical outcome of children and adults with localized Ewing sarcoma: impact of chemotherapy dose and timing of local therapy. Cancer 2010;116:31893194.

    • Search Google Scholar
    • Export Citation
  • 24.

    Oberlin O, Deley MC, Bui BN. Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer 2001;85:16461654.

    • Search Google Scholar
    • Export Citation
  • 25.

    Paulussen M, Ahrens S, Dunst J. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 2001;19:18181829.

    • Search Google Scholar
    • Export Citation
  • 26.

    Pan HY, Morani A, Wang WL. Prognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and R0 resection. Int J Radiat Oncol Biol Phys 2015;92:349357.

    • Search Google Scholar
    • Export Citation
  • 27.

    Burgert EO, Nesbit ME, Garnsey LA. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup study IESS-II. J Clin Oncol 1990;8:15141524.

    • Search Google Scholar
    • Export Citation
  • 28.

    Nesbit ME, Gehan EA, Burgert EO. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the first Intergroup study. J Clin Oncol 1990;8:16641674.

    • Search Google Scholar
    • Export Citation
  • 29.

    Grier HE, Krailo MD, Tarbell NJ. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694701.

    • Search Google Scholar
    • Export Citation
  • 30.

    Shamberger RC, LaQuaglia MP, Gebhardt MC. Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 2003;238:563567; discussion 567–568.

    • Search Google Scholar
    • Export Citation
  • 31.

    Krasin MJ, Davidoff AM, Rodriguez-Galindo C. Definitive surgery and multiagent systemic therapy for patients with localized Ewing sarcoma family of tumors: local outcome and prognostic factors. Cancer 2005;104:367373.

    • Search Google Scholar
    • Export Citation
  • 32.

    Wexler LH, DeLaney TF, Tsokos M. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer 1996;78:901911.

    • Search Google Scholar
    • Export Citation
  • 33.

    Rosito P, Mancini AF, Rondelli R. Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: a preliminary report of 6 years of experience. Cancer 1999;86:421428.

    • Search Google Scholar
    • Export Citation
  • 34.

    Kolb EA, Kushner BH, Gorlick R. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol 2003;21:34233430.

    • Search Google Scholar
    • Export Citation
  • 35.

    Oberlin O, Habrand JL, Zucker JM. No benefit of ifosfamide in Ewing's sarcoma: a nonrandomized study of the French Society of Pediatric Oncology. J Clin Oncol 1992;10:14071412.

    • Search Google Scholar
    • Export Citation
  • 36.

    Bacci G, Picci P, Ferrari S. Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase—results of two sequential studies. Cancer 1998;82:11741183.

    • Search Google Scholar
    • Export Citation
  • 37.

    Yock TI, Krailo M, Fryer CJ. Local control in pelvic Ewing sarcoma: analysis from INT-0091—a report from the Children's Oncology Group. J Clin Oncol 2006;24:38383843.

    • Search Google Scholar
    • Export Citation
  • 38.

    Paulussen M, Craft AW, Lewis I. Results of the EICESS-92 study: two randomized trials of Ewing's sarcoma treatment—cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 2008;26:43854393.

    • Search Google Scholar
    • Export Citation
  • 39.

    Le Deley MC, Paulussen M, Lewis I. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 Trial. J Clin Oncol 2014;32:24402448.

    • Search Google Scholar
    • Export Citation
  • 40.

    Granowetter L, Womer R, Devidas M. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group study. J Clin Oncol 2009;27:25362541.

    • Search Google Scholar
    • Export Citation
  • 41.

    Womer RB, West DC, Krailo MD. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2012;30:41484154.

    • Search Google Scholar
    • Export Citation
  • 42.

    Miser JS, Krailo MD, Tarbell NJ. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide—a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol 2004;22:28732876.

    • Search Google Scholar
    • Export Citation
  • 43.

    Dunst J, Jurgens H, Sauer R. Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial. Int J Radiat Oncol Biol Phys 1995;32:919930.

    • Search Google Scholar
    • Export Citation
  • 44.

    Haeusler J, Ranft A, Boelling T. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer 2010;116:443450.

    • Search Google Scholar
    • Export Citation
  • 45.

    Paulussen M, Ahrens S, Burdach S. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 1998;9:275281.

    • Search Google Scholar
    • Export Citation
  • 46.

    Casey DL, Wexler LH, Meyers PA. Radiation for bone metastases in Ewing sarcoma and rhabdomyosarcoma. Pediatr Blood Cancer 2015;62:445449.

  • 47.

    Schuck A, Ahrens S, Paulussen M. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys 2003;55:168177.

    • Search Google Scholar
    • Export Citation
  • 48.

    DuBois SG, Krailo MD, Gebhardt MC. Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children's Oncology Group. Cancer 2015;121:467475.

    • Search Google Scholar
    • Export Citation
  • 49.

    Schuck A, Ahrens S, von Schorlemer I. Radiotherapy in Ewing tumors of the vertebrae: treatment results and local relapse analysis of the CESS 81/86 and EICESS 92 trials. Int J Radiat Oncol Biol Phys 2005;63:15621567.

    • Search Google Scholar
    • Export Citation
  • 50.

    Indelicato DJ, Keole SR, Shahlaee AH. Definitive radiotherapy for ewing tumors of extremities and pelvis: long-term disease control, limb function, and treatment toxicity. Int J Radiat Oncol Biol Phys 2008;72:871877.

    • Search Google Scholar
    • Export Citation
  • 51.

    Krasin MJ, Rodriguez-Galindo C, Billups CA. Definitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: outcome and prognostic factors. Int J Radiat Oncol Biol Phys 2004;60:830838.

    • Search Google Scholar
    • Export Citation
  • 52.

    Paulino AC, Nguyen TX, Mai WY. Dose response and local control using radiotherapy in non-metastatic Ewing sarcoma. Pediatr Blood Cancer 2007;49:145148.

    • Search Google Scholar
    • Export Citation
  • 53.

    Rodriguez-Galindo C, Billups CA, Kun LE. Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999. Cancer 2002;94:561569.

    • Search Google Scholar
    • Export Citation
  • 54.

    Bacci G, Ferrari S, Longhi A. Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol 2003;14:16541659.

    • Search Google Scholar
    • Export Citation
  • 55.

    Leavey PJ, Mascarenhas L, Marina N. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: a report from the Children's Oncology Group. Pediatr Blood Cancer 2008;51:334338.

    • Search Google Scholar
    • Export Citation
  • 56.

    Ferrari S, Luksch R, Hall KS. Post-relapse survival in patients with Ewing sarcoma. Pediatr Blood Cancer 2015;62:994999.

  • 57.

    Robinson SI, Ahmed SK, Laack NN. Clinical outcomes of adult patients with relapsed Ewing sarcoma: a 30-year single institution experience [abstract]. J Clin Oncol 2011;29(Suppl):Abstract 10041.

    • Search Google Scholar
    • Export Citation
  • 58.

    Stahl M, Ranft A, Paulussen M. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 2011;57:549553.

    • Search Google Scholar
    • Export Citation
  • 59.

    Miser JS, Kinsella TJ, Triche TJ. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987;5:11911198.

    • Search Google Scholar
    • Export Citation
  • 60.

    Van Winkle P, Angiolillo A, Krailo M. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr Blood Cancer 2005;44:338347.

    • Search Google Scholar
    • Export Citation
  • 61.

    Rasper M, Jabar S, Ranft A. The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma. Pediatr Blood Cancer 2014;61:13821386.

    • Search Google Scholar
    • Export Citation
  • 62.

    Magnan H, Goodbody CM, Riedel E. Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma. Pediatr Blood Cancer 2015;62:594597.

    • Search Google Scholar
    • Export Citation
  • 63.

    Navid F, Willert JR, McCarville MB. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 2008;113:419425.

    • Search Google Scholar
    • Export Citation
  • 64.

    Bernstein ML, Devidas M, Lafreniere D. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457—a report from the Children's Oncology Group. J Clin Oncol 2006;24:152159.

    • Search Google Scholar
    • Export Citation
  • 65.

    Hunold A, Weddeling N, Paulussen M. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 2006;47:795800.

    • Search Google Scholar
    • Export Citation
  • 66.

    Kushner BH, Kramer K, Meyers PA. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. Med Pediatr Oncol 2000;35:468474.

    • Search Google Scholar
    • Export Citation
  • 67.

    Saylors RL, Stine KC, Sullivan J. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001;19:34633469.

    • Search Google Scholar
    • Export Citation
  • 68.

    Casey DA, Wexler LH, Merchant MS. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer 2009;53:10291034.

    • Search Google Scholar
    • Export Citation
  • 69.

    Wagner LM, Crews KR, Iacono LC. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 2004;10:840848.

    • Search Google Scholar
    • Export Citation
  • 70.

    Wagner LM, McAllister N, Goldsby RE. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007;48:132139.

    • Search Google Scholar
    • Export Citation
  • 71.

    Raciborska A, Bilska K, Drabko K. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma. Pediatr Blood Cancer 2013;60:16211625.

    • Search Google Scholar
    • Export Citation
  • 72.

    van Maldegem AM, Benson C, Rutkowski P. Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study. Pediatr Blood Cancer 2015;62:4044.

    • Search Google Scholar
    • Export Citation
  • 73.

    Denbo JW, Shannon Orr W, Wu Y. Timing of surgery and the role of adjuvant radiotherapy in ewing sarcoma of the chest wall: a single-institution experience. Ann Surg Oncol 2012;19:38093815.

    • Search Google Scholar
    • Export Citation
  • 74.

    Bacci G, Forni C, Longhi A. Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer 2004;40:7383.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2622 2049 166
PDF Downloads 621 519 40
EPUB Downloads 0 0 0